CDKN2A and nasopharyngeal carcinoma: Moreover, it has been reported that p16INK4a inactivation, assessed with F-12 antibody, was involved in development and progression of other malignancies such as nasopharyngeal carcinoma [24], thick melanomas [25], and adrenocortical tumours [26].